标题
Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 14, Issue 3, Pages 287-299
出版商
Informa Healthcare
发表日期
2014-01-04
DOI
10.1517/14712598.2014.867323
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
- (2013) K. Cramer-Morales et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells
- (2013) E. Bolton-Gillespie et al. BLOOD
- A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
- (2013) Daniel J. Goff et al. Cell Stem Cell
- BCL-2 Inhibition: Stemming the Tide of Myeloid Malignancies
- (2013) Leah J. Hogdal et al. Cell Stem Cell
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
- (2013) Min Chen et al. JNCI-Journal of the National Cancer Institute
- Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice
- (2012) C. Walz et al. BLOOD
- Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining
- (2012) S. Chakraborty et al. BLOOD
- Targeting of GSK3 promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells
- (2012) G. Reddiconto et al. BLOOD
- Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
- (2012) A. Agarwal et al. BLOOD
- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
- (2012) Florian H. Heidel et al. Cell Stem Cell
- Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: Key role of stromal microenvironment
- (2012) P.F. Seke Etet et al. CELLULAR SIGNALLING
- Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
- (2012) Susan Branford et al. JOURNAL OF CLINICAL ONCOLOGY
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
- (2011) G. V. Helgason et al. BLOOD
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
- (2011) E. A. Nelson et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Suboptimal responses in chronic myeloid leukemia
- (2011) Elias Jabbour et al. CANCER
- The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia
- (2011) Yaoyu Chen et al. CELL CYCLE
- BMI1 as a novel target for drug discovery in cancer
- (2011) Liangxian Cao et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
- (2011) Bing Long et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
- (2011) Christian Hurtz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
- (2011) F Pellicano et al. LEUKEMIA
- Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
- (2011) E Weisberg et al. LEUKEMIA
- BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
- (2011) Cihangir Duy et al. NATURE
- Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
- (2010) X. Jiang et al. BLOOD
- Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
- (2010) Bin Zhang et al. CANCER CELL
- Oxygen in Stem Cell Biology: A Critical Component of the Stem Cell Niche
- (2010) Ahmed Mohyeldin et al. Cell Stem Cell
- Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
- (2010) F. Vianello et al. HAEMATOLOGICA
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- BCR-ABL kinase is dead; long live the CML stem cell
- (2010) Alexander Perl et al. JOURNAL OF CLINICAL INVESTIGATION
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia
- (2010) Makoto Kashimura et al. LEUKEMIA RESEARCH
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- The leukemic stem cell niche: current concepts and therapeutic opportunities
- (2009) S. W. Lane et al. BLOOD
- A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell
- (2009) Keisuke Ito et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib
- (2009) Sophia Hatziieremia et al. EXPERIMENTAL HEMATOLOGY
- The hematopoietic stem cell niche: Low in oxygen but a nice place to be
- (2009) Pernilla Eliasson et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
- (2009) Yaoyu Chen et al. NATURE GENETICS
- β-Catenin Expression in the Bone Marrow Microenvironment Is Required for Long-Term Maintenance of Primitive Hematopoietic Cells
- (2009) Michael J. Nemeth et al. STEM CELLS
- Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
- (2008) S. M. Devine et al. BLOOD
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia
- (2008) Y Hu et al. LEUKEMIA
- Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
- (2008) H Konig et al. LEUKEMIA
- Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107
- (2008) Meir Wetzler et al. LEUKEMIA & LYMPHOMA
- CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
- (2008) L. Jin et al. MOLECULAR CANCER THERAPEUTICS
- PML targeting eradicates quiescent leukaemia-initiating cells
- (2008) Keisuke Ito et al. NATURE
- A brief introduction to FOXOlogy
- (2008) B M Th Burgering ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More